Fluence is a psychedelic education project of Liberty Learning, LLC and is fully owned and operated by Dr. Ingmar Gorman and Dr. Elizabeth Nielson. We offer training independently and in collaboration with a variety of clinics, conferences, private practices, non-profit associations, retreat centers, and psychedelic research sponsors.
Fluence offers a series of continuing education programs in psychedelic integration and psychedelic-assisted therapy. Their programs are designed for licensed professionals and advanced graduate students who have an opportunity to work with patient populations. Although none of their courses have specific prerequisites, a basic working knowledge of the mental health field and practice of psychotherapy is helpful. Fluence's programs are interactive, they engage in discussion, demonstration, self-reflection exercises, and role plays. Some of their classes and programs are reserved for licensed clinicians, but many are open anyone who wishes to attend.
Dr. Elizabeth Nielson, Co-founder & Lead Trainer
- Co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders.
- Site Co-Principal Investigator and therapist for an FDA approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder, and has served as a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, psilocybin-assisted treatment of treatment resistant depression, and earlier phase 2 and 3 trials of MDMA-assisted psychotherapy.
- Completed an NIH postdoctoral fellowship at NYU, published and presented on topics of psychedelic therapist training, therapists’ personal experience with psychedelics, and including psychedelic integration in group and individual psychotherapy.
Dr. Ingmar Gorman, Co-founder & Lead Trainer
- Received his clinical training in New York City at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital.
- Completed his NIH postdoctoral fellowship at New York University. He simultaneously served as site co-principal investigator on an FDA approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder and is currently a study therapist on the same study, as well as another FDA approved clinical trial of psilocybin for treatment resistant depression.
- Published on the topics of classic psychedelics, ketamine, MDMA, and Psychedelic Harm Reduction and Integration.